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The global surge of antimicrobial resistance (AMR) is a major concern for public health and proving to be
a key challenge in modern disease treatment, requiring action plans at all levels. Microorganisms regularly
and rapidly acquire resistance to antibiotic treatments and new drugs are continuously required. However,
the inherent cost and risk to develop such molecules has resulted in a drying of the pipeline with very few
compounds currently in development. Over the last two decades, efforts have been made to tackle the
main sources of AMR. Nevertheless, these require the involvement of large governmental bodies, further
increasing the complexity of the problem. As a group with a long innovation history, the biomaterials
community is perfectly situated to push forward novel antimicrobial technologies to combat AMR.
Although this involvement has been felt, it is necessary to ensure that the field offers a united front with
special focus in areas that will facilitate the development and implementation of such systems. This paper
reviews state of the art biomaterials strategies striving to limit AMR. Promising broad-spectrum antimicro-
bials and device modifications are showcased through two case studies for different applications, namely
topical and implantables, demonstrating the potential for a highly efficacious physical and chemical
approach. Finally, a critical review on barriers and limitations of these methods has been developed to
provide a list of short and long-term focus areas in order to ensure the full potential of the biomaterials
community is directed to helping tackle the AMR pandemic.
Introduction
Antibiotics are a precious resource capable of specifically tar-
geting microbial infections with little impact on endogenous
human cells. Since the discovery of penicillin, antibiotics have
been coined ‘wonder drugs’, helping to save hundreds of
millions of people.1,2 Today the use of antibiotics is broad and
encompasses almost every aspect of our society, including
healthcare, the food industry and agriculture. This makes it
difficult to imagine a world devoid of such fundamental sub-
stances. Nevertheless, as microorganisms continue to develop
resistance mechanisms to the use of antibiotics, termed anti-
microbial resistance (AMR), this future may become a reality.
This includes a rise in the spread of resistance to widely used
antibiotics such as vancomycin in Enterococci and an increas-
ing number of pan-drug resistant pathogens.3–5
Predictions of the global socioeconomic impact caused by
AMR have been estimated as $100 trillion per annum with a
potential loss of 10 million lives annually by 2050.6 Although
these predictions have been labelled as uncertain and pessi-
mistic,7 AMR is certainly one of the great challenges of our era.
The hazard posed by AMR has led to global action since 2001,8
however, it was not until the Global Action Plan on
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Antimicrobial Resistance was adopted at the 68th World
Health Assembly in Geneva (2015) that positive developments
have been felt.4,9 It is clear, that if we are to prevent a ‘post-
antibiotic’ era then action must be taken at all levels and
across multiple disciplines. This review focuses on steps that
the biomaterials community, as a key field of innovation for
antimicrobial substances, may take to help tackle AMR.
Bacteria have been present on this planet for 3.5 billion
years, capable of resisting and flourishing in extreme con-
ditions where more complex life is not able to prosper.10 This
adaptability stems from their large populations, rapid division
cycles, and the ability to transfer genetic information between
species.11 As a consequence, bacteria have evolved a series of
complex resistance mechanisms against toxic substances
(Fig. 1a).12,13 These tools provide a natural resilience that can
overcome antibiotic therapies, a problem noticed by Alexander
Flemming shortly after the discovery of penicillin, which led to
a warning on handling antibiotic dosages and treatment
periods.14 Whilst the mechanisms of AMR demonstrate the
adaptability of bacterial species, human overuse and misuse of
antibiotics has been largely at fault for selection of resistance
mutants and their expansion to high prevalence.
Antimicrobials work by inhibiting various essential cellular
processes and pathways. Specifically, antibiotics have class
dependant modes of action that precisely target an aspect of a
bacterial cell’s ability to survive (Table 1).15 Most antibiotic
classes were discovery between 1928 and 1987 with no new cat-
egories reaching the market since (Fig. 1b). In recent years,
handling of antibiotics has been poorly managed, with these
substances rapidly entering mass production in multiple
industries and little control over availability, indications and
dosage regimes. Due to this extensive availability and lack of
oversight or control on application there has been a great deal
of drug overuse which has exacerbated the global AMR
problem.16 Understanding of the evolution of resistance in
relation to selective pressures has improved since antibiotics
were first employed. Specifically, the critical importance of
delivering sufficient and lasting antibiotic concentrations to
completely eradicate an infection and limiting resistance is
today well appreciated. Now more than ever it is clear that the
development of novel antimicrobial substances and delivery
systems is vital to the containment and prevention of AMR, an
area in which the biomaterials field is well placed to have a
massive impact.
Once novel antimicrobial technologies are discovered, it is
necessary to begin the long and risky endeavour of gaining
regulatory approval. The prospective damage that potentially
hazardous antibiotics could cause to human health has led to
a policy of safety first from the European Medicines Agency
(EMA) and the Food and Drug Administration (FDA). As a
result, the process of taking a newly discovered drug from the
laboratory to the market requires extensive preclinical data
and three phases of clinical trials before registration of the
new product.20–22 Analysis of these pipelines shows that navi-
gating these policies and obtaining regulatory approval can
take more than a decade and cost up to $1 billion,20,21,23 gen-
erally making it unfeasible for small and medium R&D compa-
nies. Thus, antibiotic research has historically been driven by
large medical corporations, however, today few incentives are
Fig. 1 (a) Mechanisms attributed to antibiotic resistance, adapted from ReAct17 and (b) timeline of antibiotic class discovery showing the discovery
void of marketed classes.17,18
Table 1 The mechanism of action of common antibiotic classes19
Mechanism of action Antibiotic classes
Inhibition of cell wall synthesis Beta-lactams
Glycopeptides
Cyclic lipopeptides
Inhibition of protein synthesis Tetracyclines
Aminoglycosides
Oxazolidinones
Streptogramins
Ketolides
Macrolides
Lincosamides
Inhibition of DNA housekeeping Fluoroquinolones
Inhibition of RNA synthesis Rifampin
Inhibition of folic acid synthesis Sulphonamides
Trimethoprim
Disorganisation of the cell membrane Polymyxins
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in place to encourage their involvement.21 The main groups of
novel antimicrobials were found early after the discovery of
penicillin, with most antibiotic classes obtained by empirical
screening more than 50 years ago24–26 for which oxazolidinones
and cyclic polypeptides were discovered last in the late 70s and
80s, respectively (Fig. 1b).25,27 Thus, all “low hanging fruit” in
the production of antimicrobial derivations and combinations
may have been tapped. Since the discovery of new classes has
slowed, progress has often been made by modifying existing
ones to escape class-related resistances28 and the combination
of several marketed drugs (i.e. “protecting drugs”)29 to prevent
AMR while minimising the risks involved with the development
of novel drugs. Although this approach has led to many new
antibiotics entering the market, typically the ‘arms race’ con-
tinues with resistance emerging to each new derivative necessi-
tating further development and refinement.29,30
The relatively low price and treatment period associated with
antibiotics requires a significant, immediate demand of a new
drug for a company to invest in its development. Although the
number of patients requiring novel drugs for AMR is on the
rise, currently the 5% increase in Health Acquired Infections
(HAI) is not sufficient to make such an endeavour economically
attractive.21 To put this into perspective, a study by the London
School of Economics has indicated that the typical net present
value (NPV) of an antibiotic is in the region of −$50 million
compared, for example, to the development and marketing of
drugs for musculoskeletal conditions, which have an NPV of
$1.15 billion.31 These factors and statistics reveal that only 1 of
5 infectious disease products that start clinical trials will obtain
regulatory approval.26,32,33 Thus, leading to a paradox where
new antibiotic drugs are critically needed, while the antibiotic
pipeline continues to run dry. As new antimicrobials are found,
experts should be aware of the chasm between laboratory dis-
covery and marketing to ensure that promising technologies are
pushed forward. This requires building up a strong case to
capture investors and relevant stakeholders, for which it is
necessary to perform relevant tests to governmental approval
and the correlation between in vitro and in vivomodels.
The number of R&D teams experienced in discovery of anti-
biotics has been diminishing over the years as a direct conse-
quence of mergers in large pharmaceutical companies.26,33
Currently only 4 large pharmaceutical companies (Merck &
Co., Roche, GlaxoSmithKline and Pfizer) still have active anti-
biotic programmes with a limited presence of small-medium
sized enterprises (SMEs).34 Consequently, there has been a
slow and steady loss of knowledge and capacity in anti-
microbial development that, coupled with the difficulties
inherent to the development of novel antimicrobial sub-
stances, has pushed forward translation over innovation.
Sadly, this change in paradigm is not restricted to the anti-
biotic pipeline and has further been encouraged through
modifications in the regulatory approval pipeline. Medical
device regulations have changed over the years, leading to the
appearance of simpler approval guidelines, such as the pre-
market notification (PMN) or 510k by the FDA.23 These regulat-
ory pathways rely on the existence of predicate devices that are
legally marketed, with similar intended uses, documented
proof of substantial equivalences and no detrimental safety
and effectiveness differences with the novel product. These
normally require an investment between $1–5 million over 3–6
years,23 contrasting with the $45 to $150 million of capital
spent over 5–8 years 35 for the more complex Premarket
Approval (PMA) where no predicate can be found. This
reduction in economic investment coupled with the risk of
obtaining PMA approval (only 1% finally enter the market)23
has led the research community to focus their efforts on devel-
oping novel delivery systems of already approved substances or
reworks of marketed products. This prevalence of translation
has restricted innovation primarily to SMEs and universities,
enhancing the need for collaboration between the biomaterials
community and industrial partners.
Over the last two decades, the danger posed by AMR in
society has been realised, making regulatory bodies take
approaches to contain and control AMR drivers.16,36–39
Nevertheless, most changes are slow or must still deal with
bureaucratic loops, which limits their application and contrib-
utes to the increasingly pressing hazard brought by antibiotic
resistant bacteria.23 This slow pace of governance from inter-
national regulatory bodies further strengthens the importance
of tackling AMR at all levels of the pipeline, including fields
that may change the state of play such as biomaterials science.
As the main source of innovation, the research community has
taken a lead in understanding AMR, their mechanisms and
developing novel therapies.
More than 70 000 publications linked to AMR have been
issued globally, with 8575 made available solely in 2019.40
More interestingly, roughly 8% of these can be correlated with
the analysis and advancement of better antimicrobials and
therapies by the biomaterials community, showcasing an
increasing involvement (Fig. 2). Since the dissemination of the
“Global strategy for containment of antimicrobial resistance”
by the World Health Organization (WHO) in 2001,8 the
number of research publications developed by the biomater-
ials science field on AMR has risen from 23 to 676 in the 2001
to 2019 period (Fig. 2a). Alongside this the diversity of fields
that biomaterials science contributes to has evolved, with
microbiology being the largest sector showcasing a willingness
to support AMR solutions (Fig. 2b).
The aim of this review is to detail the current state of techno-
logies developed by the biomaterials research community to
tackle AMR. Two case studies are presented to highlight inno-
vation that is being driven to improve topical and local delivery
of antimicrobials. Finally, this work provides a concise list of
recommendations to ensure that progress of novel technologies
in the AMR field continues and that these game-changing
approaches may effectively infiltrate the marketplace.
Novel antibiotics
Since the void of class discovery, numerous analogues of exist-
ing antibiotics have successfully been marketed, which has pro-
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vided a short-term solution to the development of drug resistant
bacteria.41 The limited effect of such strategies has already been
highlighted by Watson,42 who found that 50% of European
deaths associated with infection in 2008, may have been due to
resistant bacteria. More recent studies suggest that this trend is
on the rise with Cassini et al.43 stating that the burden of resist-
ant infections is now closer to 75% of the total deaths caused
by infection in Europe. There is also further concern surround-
ing the rise of last-line antibiotic resistant bacteria, with 35% of
total deaths related to infection in 2019 caused by these
species.42 Thus, it is clear that new antimicrobials are needed.
Further study within medical services has shown that only
17 different microorganisms, including Enterococcus faecium,
Staphylococcus aureus, Klebsiella pneumonaie, Acinetobacter bau-
mannii, Pseudomonas aeruginosa and Escherichia coli (ESKAPE
pathogens) account for up to 87% of all HAI.44,45 With AMR
increasing and the development of new antibiotics grinding to a
halt, to help drive and guide development the WHO published
a list of 12 priority pathogens in 2017 (Table 2).46 These are the
species most likely to cause a significant impact on human
health if resistance continues to develop on its present trajec-
tory. The pathogens are graded from critical to medium with
those in the critical category resistant to multiple antimicro-
bials, including carbapenem (a ‘last resort’ antibiotic), posing
an imminent threat to health.46,47 In addition to the organisms
prioritised by the WHO, the Centre for Disease Control and
Prevention (CDC) also identifies Candida auris and
Clostridioides difficile (C. difficile) as urgent threats to healthcare.
According to The Pew Trust, as of December 2019 approxi-
mately 41 new antibiotics are in Phases 1–3 of development.48
This suggests that the drug development pipeline has been rein-
vigorated, although the number of substances that gain
approval may of course be much lower. Historic data suggests
only 20% of these new antibiotics will make it to market49 with
only 11 of these being a novel class or targeting a new mecha-
nism. Furthermore, only 6 of those have expected activity
against WHO or CDC priority pathogens (Table 3),48 limiting
the prospects of novel antibiotics available to tackle AMR.
The discovery of penicillin later led to the creation of many
derivatives, built with the intention of circumventing the issue
of penicillin-resistant bacteria.50 Further advances were also
made in the development of antibiotics delivered in conjunc-
tion with anti-bacterial resistance factors. Such an approach
was taken by adding clavulanic acid, which inhibits beta-lacta-
mase resistance, to amoxicillin.51 However, there is a limit to
the number of different analogues that can be synthesised
from a single chemical core and even more so on those that
can counteract bacterial resistance mechanisms. Many other
antibiotics have undergone analogue development, with some
more amenable than others.52 Beta lactams have been the
most successfully derived antibiotics with many analogues
containing penicillin or cephalosporin cores, although the qui-
nolone and aminoglycoside classes have also provided numer-
ous alternatives.19 Unfortunately, rapid evolution and develop-
ment of bacterial resistance has been shown in all cases,
negating the effects of even the most ingenious medicinal
chemistry solutions.19,52
Biomaterials strategies
As previously highlighted, there has been a global culture of
misuse and overreliance on antibiotics, surrounded by a
Fig. 2 Number of publications for AMR materials ordered by (a) year
and (b) research area. Source “Web of Science”.
Table 2 World Health Organisation priority pathogens46
Critical
Acinetobacter baumannii – carbapenem resistant
Pseudomonas aeruginosa – carbapenem resistant
Enterobacteriaceae – carbapenem resistant, extended-spectrum beta-
lactamase producing (ESBL)
High
Enterococcus faecium – vancomycin resistant
Staphylococcus aureus – methicillin resistant, vancomycin intermediate
and resistant
Helicobacter pylori – clarithromycin resistant
Campylobacter spp. – fluoroquinolone resistant
Salmonellae – fluoroquinolone resistant
Neisseria gonorrhoeae – cephalosporin resistant, fluoroquinolone
resistant
Medium
Streptococcus pneumoniae – penicillin non susceptible
Haemophilus influenzae – ampicillin resistant
Shigella spp. – fluoroquinolone resistant
Review Biomaterials Science
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‘magic bullet’ ethos where these compounds were viewed as the
only solution to microbial infections. Nonetheless, the pipe-
line for novel classes of antibiotics is very poorly populated,
limited by regulatory processes and the complex mechanisms
behind antibiotic resistance. The development of next gene-
ration antibiotics is vital to the future of medicine; however,
other alternatives and methodologies must be employed in
order to both reduce the use of antibiotics and slow the devel-
opment of resistance. In this regard, the biomaterial commu-
nity has a long history of developing and innovating solutions
to healthcare challenges. Current ongoing research is focused
in various different areas including the development of
alternative antimicrobials, modification of device surfaces and
the improvement of delivery systems (Fig. 3), posing a prime
example of game-changing research that this community has
to offer against AMR emergence.
Alternative antimicrobials
The goal of developing antimicrobial materials is to produce a
biocompatible product adept at inhibiting or killing micro-
organisms that may colonise the surface of a material or the
surrounding area without the development of resistance.
Before the discovery and introduction of antibiotics in medi-
cine, natural antimicrobials such as metallic ions and honey
were routinely used for the treatment and prevention of infec-
tion, with use dating back millennia.53–55 During the upcom-
ing of the antibiotic era these substances where rapidly substi-
tuted, however, renewed interest in such materials is motivated
by a hope to reduce the current burden of AMR on global
healthcare.
Unlike traditional antibiotics that have specific modes of
action and provide an ease of progressive resistance, both
antimicrobial metallic ions and honey target multiple cellular
processes and lead to pleiotropic effects within the target
organism.56–58 In the case of metallic ions, it has been shown
that these certain elements, including silver, copper or
arsenic, are capable of interfering with enzyme activities, dis-
rupting membrane functions or damaging DNA, complicating
resistance development.59,60 For most transition metals, this
is further enhanced by involvement in reactive oxygen species
(ROS) generation, which elicit its antimicrobial action
through reactions with thiol groups, oxidation of cell walls
and membranes, inhibition of protein synthesis and disrup-
tion of electron transport.61–65 These mechanisms have
encouraged research on transition metals of the d-block, (i.e.
Cu, Zn, Ag, Cd) and other metals and metalloids from groups
13–16 (i.e. Al, Ga, Ge, As).60 Nonetheless, the potential toxicity
of such elements to human tissue has limited the applica-
bility of most metals. This is the case for copper, with sur-
faces of the pure element capable of killing bacteria in mere
minutes.66 However, its prospective cytotoxicity has reduced
its wider implementation, limiting it to niche uses like touch
surfaces.55 Other antimicrobial metals with high potency that
are safer to the human body have been historically preferred,
silver being the most prominently used in healthcare
applications.67
Table 3 Novel antibiotic classes currently in global clinical development phases48
Drug name Drug class Target
Activity against
ESKAPE pathogens?
Activity against WHO or CDC
priority pathogens
Gepotidacin Triazaacenaphthylene Type II topoisomerase (novel A
subunit site)
Yes: S. aureus Yes: Drug-resistant
N. gonorrhoeae
Possibly: ESBL
Ridinilazole Bis-benzimidazole Inhibition of cell division and
reduction of toxin production
No Yes: C. difficile
Zoliflodacin Spiropyrimidinetrione Type II topoisomerase (GyrB) Yes: S. aureus Yes: Drug-resistant
N. gonorrhoeae
MGB-BP-3 Distamycin DNA minor groove binder Possibly: E. faecium, S.
aureus
Yes: C. difficile
CRS3123 Diaryldiamine Methionyl-tRNA synthetase Yes: E. faecium,
S. aureus Yes: C. difficile
Ibezapolstat
(ACX-362E)
Dichlorobenzyl guanine
(DCBG)
C. difficile DNA polymerase IIIC No Yes: C. difficile
Fig. 3 Biomaterial driven strategies for reduction of antimicrobial
burden and AMR acquisition.
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More recent developments have seen the formulation of
other antimicrobial compounds for which polymers and pep-
tides have awakened the interest of the biomaterial commu-
nity. Antimicrobial polymers are emerging within the bio-
medical field as a direct consequence of their wide appli-
cations in the treatment and prevention of infection, either
alone or in conjunction with other active substances.68 The
mechanism of action is dependent on formulation; however
the majority of polymers interact with the charge on the
surface of the microbial cell, disrupting transport, inhibiting
protein synthesis and in some cases stripping the membrane
completely causing contents leakage.69 Common antimicrobial
polymers include chitosan, heparin, ε-polylysine, polyacryl-
amides, polyacrylates, polysiloxanes, polyionenes and polyoxa-
zolines for which thorough reviews are available in the
literature.70,71
Similar to the mechanisms of action for antimicrobial poly-
mers, antimicrobial peptides (AMPs) tend to target the cell
membrane of microbes, however, they may also disrupt cellu-
lar metabolism and target components within the cytoplasm.72
AMP’s are usually amphiphilic consisting of both hydrophilic
and hydrophobic groups. This grants the molecule solubility
in aqueous environments and allows passage through lipophi-
lic membranes73 with different formulations available
(Table 4).
The attractiveness of AMP’s as versatile antimicrobial
agents has been further increased by their influence in various
biological processes, including immune and anti-inflamma-
tory responses, causing a recent shift in terminology to host
defence peptides (HDPs) to recognise their multi-functional
nature.74 As a consequence, the development of HDPs has pro-
gressed from simple contact killing or biocide releasing
materials common in first generation polycations derived from
quaternary ammonium compounds (QACs)75 to more complex
multifunctional antimicrobials such as multifunctional hyper-
branched polyaminoglycoside for improved antibacterial
activity, biocompatibility, and gene delivery.76 A specific
notable example of the flexibility of more modern HDPs can
be seen in the nylon-3 polymers development by Liu et al.77
These multifunctional polymers are capable of fine tuning the
hydrophobicity, charge density, and conformational propensity
of the material to selectively target specific bacteria while pro-
viding low hemolysis and minimal cytotoxicity. Further broad
advancements in HDPs may be found in reviews by Ding
et al.,68 Haney et al.74 and Ge et al.78 Albeit promising, histori-
cally these types of antimicrobials have had significant disad-
vantages, such as short or limited periods of activity, tissue
toxicity, high manufacturing costs and a poor ability to func-
tion in an ever changing healthcare environment.73 However,
given the current global AMR problem, these technologies are
re-emerging within the biomaterials community with hope
that they offer a new generation of antimicrobials and anti-
microbial devices.
To overcome the inherent issues of HDPs, recent advances
have been made in synthetic forms that are able to emulate
specific amino acid sidechains, overall charge, molecular
weight and three dimensional structures, retaining the pro-
perties of their natural counterparts.91 Of particular utility is
the ability to modify the properties of these synthetic HDPs to
enhance therapeutic outcomes. Some examples are the helical,
cationic polypeptides developed by Xiong et al.92 or the struc-
turally nanoengineered antimicrobial peptide polymers
(SNAPPs) reported by Lam et al.93 and Shirbin et al.,94 capable
of selectively eliminating bacteria while reducing side effects
to mammalian cells. Further research in this area has also
demonstrated the ability of polypeptides to include alternative
killing mechanisms to conventional HDP structures. Such is
the case of poly(2-oxazoline) (POX) a mimicking peptide that
enacts its antimicrobial effect by promoting reactive oxygen
species (ROS), limiting the prospects of AMR development.95
These examples clearly highlight the novelty and growing
potential of HDPs, for which more detailed information can
be found in the literature.68,96,97
Surface modifications
Biomedical devices are a crucial part of modern medicine and
the global use of for example stents, valves, artificial joints and
other implantables is increasing yearly.98 However implanted
device surfaces are susceptible to bacterial adhesion and
biofilm growth, potentially compromising the materials effec-
tiveness.99 Such infections frequently fail to respond to sys-
temic antibiotics and require invasive revision surgeries con-
sisting of debridement in conjunction with long-term anti-
biotic treatment. These revision procedures have a success rate
between 30 to 50% 100,101 with detrimental effects on the
patient’s recovery prospects alongside a heavy economic
impact to the healthcare system. It has been found that the
surface topography and degree of implant roughness has a sig-
nificant effect on the attachment of micro-organisms, and
therefore on biofilm formation.102,103 Other factors that
further dictate colonisation may include electrostatic inter-
action, wettability, van der Waals forces and steric
hindrance.104,105 Thus, the development of surfaces capable of
preventing bacterial attachment and proliferation has become
a relevant niche for biomaterial scientists.
Several studies have attempted to mimic the nano-textured
topologies present in nature that demonstrate inherent anti-
attachment properties leading to anti-biofouling or bacteri-
Table 4 Common antimicrobial peptides and their antimicrobial
activity
Antimicrobial peptide Antimicrobial activity Ref.
Magainin Bacteria, fungi, viruses 79–81
Cecropin Bacteria, fungi, viruses 82–84
Brevinin-1 Fungi, and viruses 85 and 86
PMAP-23 Fungi 79 and 87
Protegrin Bacteria and viruses 80 and 81
Dermaseptin Viruses 82 and 83
Tachyplesin Viruses 84 and 85
Polyphemusin Viruses 86 and 88
Tenecin-3 Fungi 89
PR-39 Bacteria 90
Review Biomaterials Science
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cidal surfaces.105 Some examples of plant and animal species
exhibiting these characteristics can be found on the leaves of
taro and lotus plants as well as shark skin.106,107 These sur-
faces prevent bacterial colonization through superhydrophobic
structures and anisotropic flow patterns at both micro and
nano scales, which allow for the repulsion of microbes on the
surface.108,109 Consequently, these topologies confer a “self-
cleaning” ability, reducing further proliferation of bacterial
species. In contrast to antifouling, other natural topologies
can interact with the cell membrane of the deposited bacteria,
leading to its disruption and cell death. This is the case for the
cicada wings and the skin of geckos110–113 that exhibit nano-
scale pillar structures capable of piercing the cell walls of
microorganisms.114,115 Interestingly, both antifouling and anti-
bacterial properties can be present on the same surface. Some
species of dragonfly combine both mechanisms on their wings
for high anti-attachment and bactericidal effects.116
Nevertheless, microbial attachment is a complex process
dependent on numerous physicochemical properties and
differs between bacterial species with limited knowledge avail-
able in the literature. Research by Ginestra et al.117 and
Villapún et al.118 both discuss the necessity of combining
physical and chemical approaches to effectively prevent and
treat medical device infections. The current research on metal-
lic implants is pointing out the possibility of fine tuning the
topology and chemistry of biomaterials with natural anti-
microbial properties to increase effectiveness.118,119 Thus,
surface alteration of inert and antibacterial surfaces is becom-
ing more prominent in the biomaterial community.
Antimicrobial delivery systems
The complex problem of AMR is likely to require a multi-
faceted approach from the biomaterials community with con-
siderations taken at many different levels.120 One area of
concern is the delivery of antimicrobials and how dose and
material release kinetics are optimised to minimise resistance
(Fig. 4). The mutant selection hypothesis121,122 theorises that
antimicrobial resistant subpopulations present before the start
of a treatment regime are enriched and amplified when dosing
commences if the concentration falls within a specific range
(Fig. 4a), known as the mutant selection window. The upper
limit of this range is determined by the mutant prevention
concentration (MPC), which represents the minimum inhibi-
tory concentration (MIC) of the test antimicrobial against the
least susceptible mutant present within the population.123 The
lower limit of the mutant selection window is determined by
the lowest concentration that is still able to exert selective
pressure on the microorganism.124
From the mutant selection hypothesis, the biomaterials
community can take two main principles. Firstly, traditional
antimicrobial dosing strategies that aim to stop the develop-
ment of resistance by killing susceptible cells still allow for the
enrichment of resistant pathogens when the concentration of
the treatment falls within that window.125 Secondly, if the
maximum concentration (Cmax) of the antimicrobial exceeds
and maintains above the mutant selection window, it should
restrict the development of AMR for the treatment regime.124
These two principles are critical to the design of biomaterials
and the dosing strategies they permit in order to treat infec-
tions not already resistant to the antimicrobial being used.
Although seemingly straightforward, application of the
mutant selection hypothesis is not so simple due to the large
doses required (>MPC). It is necessary to consider that the con-
centrations required to minimise resistance development are
often far higher than what is needed to treat the infection. At
these high doses, antimicrobials may also present a number of
side effects to the patient with a trade-off between an increased
risk of toxicity in exchange for the reduced likelihood of devel-
oping a resistant infection.124 Moreover, if the antimicrobial is
dosed infrequently or the components are long lasting the con-
centration may end up falling within the mutant selection
window. It is expected that AMR will develop faster in these
instances than those microorganisms treated more regularly
with concentrations maintained above the mutant selection
window.126,127 As such, the selection of an optimal dosing
profile for the biomaterial is crucial in AMR prevention.
Fig. 4 Graphs showing (a) definition of the mutant selection window for an antimicrobial dosage and (b) dosage regimes.
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Generally, there are two prevalent pharmacokinetic dosing
profiles (Fig. 4b), those which begin at a high concentration
and gradually decrease (Fig. 4b(i)) and those that start at a low
concentration and gradually increase (Fig. 4b(ii)). The first
profile is often preferred since it minimises the chance of
developing microbial resistance, however as the concentration
of the dose gradually begins to fall, the time spent close to or
within the mutant selection window increases.125 An alterna-
tive solution of a short pulse kinetic profile has been proposed
by Baker et al.,128 aiming to minimise the time that the organ-
ism has to select for resistance while simultaneously reducing
pathogen abundance due to the high antimicrobial concen-
tration (Fig. 4b(iii)). To further add to these dosing profiles, it
may also be beneficial to use combination therapies involving
two or more antimicrobials.129 This would allow high levels of
protection to be maintained since when one concentration of
antimicrobial falls below that of the MPC, another takes its
place, providing good pharmacodynamic overlap. It is also
worth noting that AMR can be selected during treatment,
therefore this type of therapy may also be useful when anti-
microbial-resistant genes are transmissible and can be gained
by an infecting bacterial population.130–132 However, difficul-
ties in joint dosing, toxicology monitoring and pharmacoki-
netics make combined administration complicated.
Based on the impact of AMR and the limited prospects of
future antibiotics being marketed, it is critical to develop novel
antimicrobial substances and remodel current delivery systems
to prevent resistance acquisition. To showcase the promising
solutions identified by the biomaterials field, two case studies
have been prepared. The first highlights research into dermal
systems, while the second focuses on bone cement, revealing
differences in approach linked to specific body areas. At the
same time, limitations in current methods and attitudes will
be introduced to propose recommendations for the develop-
ment of a united front within the biomaterials field against
AMR.
Case study I: topical applications
Topical wound care has improved and evolved over many years
with a shift in practise from drying the wound site using absor-
bent gauze to strategies that focus on maintaining a moist
healing environment.133 This change in therapeutic process
was brought about by observations made in 1962 by Winter134
and later supported by Cho et al.135 in 1998, where studies
found that occluded wounds required less time for reepithelia-
lisation than those allowed to air dry. By using a closed dres-
sing, the wound is continuously exposed to growth factors, pro-
teinases and chemotactic factors.136 This type of environment
also preserves the electrical gradient across the wound site,
allowing for the stimulation of fibroblasts and permitting epi-
thelial cell migration.133
Over the last decades, these134,135 findings have pushed
forward the development of different biomaterials for wound
healing. Today, dressings are often divided into two categories
passive and interactive. Passive dressings, such as a gauze,
deliver no clinically recognised effect on the wound itself other
than providing protection from the environment.137 Interactive
dressings are designed to actively stimulate the wound bed to
support optimal healing conditions.133 The added functional-
ity of interactive dressing have made it a focus point for the
biomaterials community with different strategies being devel-
oped to manipulate the wound environment, which now
extends beyond speeding up re-epithelialisation. Other promis-
ing functionalities that have been engineered include stimu-
lation of collagen synthesis, formation of a hypoxic environ-
ment to promote angiogenesis and strategies to decrease
topical pH, which may reduce infection incidence.138,139 In
addition, modern dressing designs also factor in patient
comfort, convenience of application and cosmetic outcomes,
such as the reduction of scarring.140–142
With the realisation that maintaining a moist environment
is beneficial for wound healing, some products have been
designed to be moisture retentive, which may be quantified
using the moisture vapour transmissions rate (MVTR).
Dressings that have a MVTR of <840 g m−2 over a 24 hours
period are described as moisture retentive.143,144 This has led
to a multitude of products on the market; however, it is noted
that none can be described as ideal for all wounds (Table 5).
Although modern occlusive dressings aim to reduce
microbial colonisation of the wound by employing mecha-
nisms to reduce pH and create unfavourable conditions for
microbial growth, topical infection is still a huge clinical
problem. Infections have historically, in the pre-antibiotic era,
been one of the leading causes of death globally with dermal
Table 5 Commercially available wound dressings145
Dressing type Commercially available products Characteristics
Gauze Curity, Vaseline Gause, Xeroform Can dry wounds
Films Bioclusive, Blisterfilm, Cutifilm, Flecigrid, OpSite, Tegaderm Retains moisture
Hydrocolloids Aquacel, Comfeel, DuoDERM, Granuflex, Tegasorb Traps fluid
Hydrogels Carrasyn, Curagel, Nu-gel, Purilon, Restore, SAF-gel, XCell Rehydrates wound
Foams 3 M Adhesive Foam, Allevyn, Lyofoam, Tielle Moderately absorbent
Alginates Algisite, Kaltostat, Sorbsan, Tegagen Highly absorbent, acts as a
haemostatic agent
Fibre mat Aquacel Hydrofibre Highly absorbent
Skin
substitutes
Alloderm, Apligraf, Biobrane, Bioseed, Dermagraft, Epicel, EZ Derm, Hyalograft, Integra
omnigraft, Laserskin, Myskin, TransCyte
Provides growth factors and
cytokines
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trauma (i.e. burns, insect bite, surgical wounds or even a
simple scratch) often proving fatal if infected.146,147 After the
discovery of penicillin, the number of individuals dying from
topical infections significantly reduced, with current estimates
suggesting that only 7–10% of hospitalised patients are
affected with dermal infections.148 Within a healthcare
environment one of the leading causes of topical infections
can be found at a surgical site (surgical site infection – SSI).
This can occur in up to 5% of patients undergoing ‘clean’ sur-
geries and up to 20% in those undergoing intra-abdominal
surgeries, affecting upwards of 300 000 people annually in the
United States alone.149,150 Among the increased morbidity
associated with an SSI, it also delays healing, which may
prolong hospital stays and return to normal activities causing
further knock on negative effects to healthcare resources, the
economy and patient well-being.
One of the most common pathogens associated with SSIs is
S. aureus, which can colonise and be carried by healthy indi-
viduals, often in the nasal cavities without detrimental
effect.151,152 These bacteria can be found relatively easily, with
20% of healthy people designated as chronic carriers, 30%
intermitted carriers and 50% not susceptible.152 More distres-
sing is that carriers are up to 12 times more likely to contract
an infection than non-carriers.148 To prevent and treat such
infections, the biomaterials community have sought to func-
tionalise topical dressing with various antibiotics, including
ciprofloxacin (CIP), tetracycline, mupirocin, fusidic acid and
gentamicin are commonly used153,154 (Table 6). This is exem-
plified by the work of García et al.155 whereby 1% chitosan
films were modified using weisocyanate to provide a carrier for
CIP. These films were found to inhibit bacterial growth with
activity levels proportional to antibiotic content. Similar thera-
peutic responses had been reported by Li et al.156 who devel-
oped CIP loaded electrospun fibre mats using thermo-
responsive polymers poly(N-isopropylacrylamide) and poly(l-
lactic acid-co-ε-caprolactone)(PCL). Alternative approaches
include cellulose scaffolds loaded with tetracycline hydro-
chloride with the ability to inhibit and reduce the growth of
bacteria as tested by disc diffusion and plate count method-
ologies.157 Furthermore, hydrogel dressings have also been
investigated for their ability to be functionalised to deliver
tetracycline, as demonstrated by Chen et al.158 In this work, it
was shown that alginate-chitosan hydrogel dressings with
incorporated gelatin microspheres containing tetracycline
hydrochloride provide a more sustained controlled release,
fundamental for AMR prevention. Interestingly, a semi-deriva-
tive of tetracycline (tigecycline) was developed to treat skin and
soft tissue infections, which avoids the efflux-mediated resis-
tance mechanism exhibited by both Gram positive and Gram
negative bacteria.159,160 Dhanalakshmi et al.161 formulated
chitosan nanoparticles loaded with tigecycline and coated
with lectin to provide a more sustained antimicrobial release
profile. More recently Nimal et al.162 further developed this for-
mulation by incorporating tigecycline-chitosan nano particles
into a platelet rich plasma hydrogel. This system demonstrated
improved antibacterial efficacy in comparison to other wound
dressings. Thus, it is clear that wound dressings have been a
particular medium used by the biomaterials community to
deliver antimicrobial molecules.
Delivering antibiotics locally to wound sites could be prefer-
ential to systemic deliver for a number of reasons. Antibiotics
need to be dosed to achieve a sufficient level of systemic
efficiency, which can often lead to toxic reactions such as that
of cumulative organ and cell toxicity. Topical delivery can
provide better tissue compatibility, a lower occurrence of resis-
tance and less wound healing interference.153 In addition, the
use of lower doses reduces the risks associated with systemic
toxicity and can overcome problems related to poor blood cir-
Table 6 Antibiotic functionalised wound dressings
Antibiotic Dressing type Materials Ref.
Ampicillin Electrospun fibre mat PCL 163
Hydrogel PVA/alginate 164
Cefazolin Electrospun fibre mat Gelatin 165
Ceftazidime Electrospun fibre mat Silk fibroin/gelatin 166
Film Guar gum/ethylenediamine/collagen 167
Ciprofloxacin Electrospun fibre mat Polyvinylpyrrolidone 168
Polyurethane/dextran 169
Doxycycline Film Collagen/gelatin 170
Gentamicin Electrospun fibre mat Chitosan 171
Moxifloxacin Electrospun fibre mat PVA/alginate 172
Neomycin Electrospun fibre mat Poly(styrene sulfonic acid-co-maleic acid)/PVA 173
Norfloxacin Film Chitosan 174
Streptomycin Electrospun fibre mat Polyurethane/cellulose acetate/zein 175
Hydrogel PVA/cellulose 176
Sulfadiazine Film Alginate/cellulose 177
Electrospun fibre mat PCL/PVA 178
Film Alginate/cellulose 177
Sulfanilamide Fibre mat Alginate 179
Tetracycline hydrochloride Film Cellulose 157
Hydrogel Alginate/chitosan/gelatin 158
Vancomycin Hydrogel Silk fibroin/gelatin 180
Film Alginate/gelatin/halloysite nanotubes 181
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culation such as that found in wounds located in the body’s
extremities.182 However, there is increasing concern around
the development and subsequent threat caused by AMR. As
such the healthcare industry has seen a revived interest in
promising natural topical wound care agents, such as silver
and honey, for both prophylactic and therapeutic use.183
For millennia honey has been used to treat topical wound
infections with AMR not reported in the available
literature.184–187 The antimicrobial effects of honey are often
attributed to a low pH (pH 3.2–4.5), high osmolarity and more
notably the presence of peroxide or non-peroxide
components.57,58 Non-peroxide honeys, such as Manuka are
monofloral and dependant on one source of nectar, in this
case from the Manuka tree.188 Increased levels of methyl-
glyoxal (MGO), methylsyringate and bee defensin-1 are found
within this type of honey, which results in a strong anti-
microbial effect.189–191
Alternatively, there are other honey systems that instead of
MGO utilise hydrogen peroxide (H2O2) and other ROS to
produce an antimicrobial response. This compound arguably
provides honey with its most potent antimicrobial mecha-
nism.192 Similar to MGO in Manuka honey, ROS has also been
found to support wound healing, specifically the process of
angiogenesis, and to act as an anti-inflammatory.193–196
However, ROS is produced in the presence of water and there-
fore as a product makes it water sensitive and less stable than
Manuka, further introducing batch to batch variation and lim-
iting clinical adoption.
The bactericidal behaviour of Manuka and ROS producing
honey, both in vitro and in vivo, has been extensively
researched and against a diverse range of pathogenic organ-
isms. This includes WHO priority pathogens such as MRSA
and vancomycin-resistant Enterococcus faecium,197–203 increas-
ing the interest in its application to tackle AMR. Further to
testing efficacy, attempts were made to generate strains of bac-
teria resistant to Manuka honey, however it was unsuccessful
with no reports of clinical isolates that acquired resistance by
both Blair et al.204 and Cooper et al.187 In addition to inhibit-
ing planktonic cells, Manuka and ROS honey was also found
to disperse, disrupt and kill bacteria within forming and estab-
lished biofilms. This included preventing the formation of bio-
films of Staphylococcus and Streptococcus species, Pseudomonas
aeruginosa, Escherichia coli, Acinetobacter baumannii and
Klebsiella pneumonia, clearly indicating strong clinical
potential.200,205–208
Albeit their antimicrobial properties, the advent of highly
efficacious antibiotics in the 20th century led to a diminished
interest in applying honey in wound care. A key explanation for
the reduced use of honey as a wound care treatment, like most
naturally occurring antimicrobials, is its physical properties
and characteristics, which are not compatible with modern
day medicine or suitable for delivery in a clinical setting. With
the rapid emergence of AMR the biomaterials community has
taken a step forward to formulate delivery systems for natural
antimicrobials that exist in undesirable forms. Medical grade
Manuka honeys, such as Activon and Medihoney, are com-
monly used to impregnate or coat wound dressings. This is
exemplified through the work of Taher et al.209 and Kamaratos
et al.,210 which utilise nanocellulose and tulle dressing respect-
ively as a carrier for honey products. On the other hand,
research such as that by Mancuso et al.,211 has taken this a
step further through the development of biomimetic meshes
containing Manuka honey. This work demonstrated the poten-
tial to develop a layer-by-layer assembly of nanocoated poly(ε-
caprolactone) mesh, which elicited biocompatibility and anti-
microbial behaviour.
Despite the water sensitivity of ROS producing honey bio-
material scientists have pushed forward the development of
novel strategies to increase the presence of this type of honey
in wound care. Research by Febriyenti et al.212 and
Khounganian et al.213 explored formulating honey gels in
order to ease delivery and stimulate wound healing. In both
cases ROS producing honey gel shortened the wound healing
time significantly and produced no negative side effects when
compared with untreated and nondisclosed commercial pro-
ducts. However, the antimicrobial capacity of the formulation
was not addressed. In order to realise the potential of ROS pro-
ducing honey as a viable topical antimicrobial treatment, it
must be capable of delivering specific and controlled amounts
of the antimicrobial agent over a clinically relevant period.
Surgihoney™ (SHRO), a bioengineered honey has been formu-
lated to enable delivery of consistent antimicrobial doses.214
The antimicrobial effect of SHRO has also been demon-
strated with clinical tests highlights its ability to prevent and
treat SSIs as well as Hickman and Vascular line infections
without the need for antibiotic administration.215,216 As afore-
mentioned, SHRO is an engineered honey, allowing the
potency to be tailored as required. This ‘dialling’ enabled
SHRO to be modified such that it outperformed other medical
grade honeys, including Activon and Medihoney, and two of
the most commonly used antimicrobials dressings, silver and
iodine.197 Although SHRO addresses the need to provide a
medical grade honey product that can deliver a consistent dose
of antimicrobial activity, its uptake clinically, much like
Manuka honey, is hindered by its viscous and adherent pro-
perties. Therefore, in order for honey to become a more viable
clinical treatment new delivery systems must be developed
where the biomaterials community has significant expertise.
To date research by Hall et al.,202 has demonstrated a clinically
efficacious emulsion system capable of easing the delivery of
SHRO using an inversion trigger. This showcases that by
engineering biomaterial delivery systems with appropriate
physicochemical properties we may be able to better harness
the antimicrobial efficacy of honey.
Furthermore, as well as using honey as a sole antimicrobial
agent, its interactions with conventional antibiotics has
revealed some promising results. Particular value may be
sought in the topical application of honey to a wound along-
side systemic delivery of an antibiotic. Jenkins et al.217 noted
synergistic effects between Manuka honey and a range of anti-
biotics, including oxacillin, tetracycline, imipenem and mupir-
ocin against strains of meticillin-resistant Staphylococcus
Review Biomaterials Science
Biomater. Sci. This journal is © The Royal Society of Chemistry 2020
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
1 
A
ug
us
t 2
02
0.
 D
ow
nl
oa
de
d 
on
 8
/2
6/
20
20
 2
:2
8:
12
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
aureus (MRSA). Interestingly, it was found that the addition of
honey caused the down regulation of mecR1, a gene that
encodes for an MRSA specific penicillin binding protein
(PBP2A) and in combination with oxacillin made MRSA once
more susceptible to the antibiotic. Furthermore, Müller
et al.218 discovered strong synergistic activity of Manuka honey
and rifampicin against numerous Staphylococcus aureus
strains, including clinical isolates of MRSA. It was also found
that the presence of Manuka honey prevented the development
of rifampicin resistance in vitro. However, despite displaying a
strong clinical potential, inconsistency in efficacy due to the
natural origin of Manuka honey and its physical characteristics
make consistent application difficult and appear to limit
healthcare adoption.
It is clear that the biomaterials community plays a critical
role in developing more clinically useful systems that maintain
the efficacy of natural antimicrobials, such as honey. Future
considerations should focus on developing biomaterials
reflecting on how dosage may be controlled to maintain con-
centrations above the MPC. With the aid of the biomaterial’s
community further development of efficacious treatments can
be achieved while also endearing to learn from our previous
use of antibiotics.
Case study II: bone cements
The prospect of an infected device caused by an antibiotic re-
sistance species is of great relevance to implantable techno-
logies. In topical applications, changes of antimicrobial agent
can be easily performed. However, access to an implantable
for modification of ongoing therapeutics is complex and
costly. Alongside the biological and mechanical requirements
of these systems, implantable devices require special consider-
ations from the biomaterials community.
Since the first successful long bone reconstructions per-
formed in the 19th century, the field of orthopaedics has
evolved through the implementation of novel techniques and
biomaterials, nevertheless, infection is still a major concern in
the 21st century.219 Between 1 to 5% of contemporary indwel-
ling prostheses have been shown to develop an infection.
Frequently removal of the implanted device and debridement
of the surrounding tissue is required.220 During revision a
patient’s movement may be impaired or limited, which can
impact long-term recovery, increase healthcare costs and
reduce economic contributions. More worrying is the adapta-
bility showcased by bacterial isolates present in these clinical
settings. Pathogens recovered from implantable orthopaedic
devices are often characterized by virulence factors that encou-
rage adhesion and biofilm formation.221,222 Once such a com-
munity environment is formed, the effectiveness of antibiotic
treatment is greatly reduced, leading to a higher infection risk
with only 30 to 50% of revision surgeries successful in remov-
ing the infection source.100,223,224 The consequences of these
hard to treat infections has resulted in the emergence of
complementary therapies to antibiotic prophylaxis. The prime
example of this approach is antibiotic-loaded bone cement
that enables localised delivery of cargo to the implant surface
and adjacent tissue.
Historically, the term bone cement has been used as a
synonym for polymethyl methacrylate (PMMA) based formu-
lations. These materials are commonly supplied as a liquid
monomer and powder polymer with mixing resulting in the for-
mation of a tacky substance that is easily manipulated and
formed.225,226 Over the years, more complex formulations have
been developed, generally including additives to prevent leach-
ing of the liquid monomer, stabilization under light and heat,
to facilitate cold curing, and increase imagining contrast or
render the cement radiopaque. As a result, PMMA cements are
a versatile biomaterial for prosthetic cementations, spacer man-
ufacture and reconstructions with commercial products avail-
able since the early 70s.227,228 More recently, there has been a
special interest in the incorporation of antibiotics during the
mixing process. However, the inherent exothermic reaction of
PMMA coupled with the impact of antibiotic selection and
dosage on the physicochemical properties of the cement
requires careful consideration. The selected antimicrobial mole-
cule must be chemically and thermally stable to maintain its
antibacterial efficacy after curing. Moreover, it has been
suggested that the antibiotic should be provided in powder
form to facilitate integration during mixing and minimise the
influence on mechanical properties.226,229,230 This has led to a
preference in the use of vancomycin, gentamicin, erythromycin,
colistin, tobramycin, clindamycin or fusidic acid with an incli-
nation for mixtures between different antibiotics for improved
bacterial spectrum.227,228,231 Dosage selection must be high
enough to ensure an effective therapy with minimal reduction
in mechanical properties and limited detrimental effect on the
human body. For this purpose, it is a common rule of thumb to
incorporate more than 2 g per 40 g of cement (up to 6 or 8 g)
for acute infections, while less than 2 g of antibiotic is accepta-
ble for prophylaxis of first implants.226,227,232,233 The addition
of such substances is commonly done in theatre, however the
approval of low-dose antibiotic loaded bone cements by the
FDA for second-stage reimplantation after infected arthroplas-
ties in 2003 has led to commercially available pre-loaded pro-
ducts from Howmedica (Antibiotic Simplex), DePuy (CMW1
and CMW 3G), Merck (Copal and Palamed G) and Schering-
Plough (Palacos R-G).226,234
Antibiotic loaded bone cements may be able to reduce resis-
tance by the rapid elimination of pathogens through a mixture
of antibiotics, nonetheless, inadequate elution profiles and
concentrations can result in resistance acquisition. The ration-
ale behind current antibiotic elution processes stems from the
necessity to rapidly eliminate latent bacteria attached to the
implant or introduced during surgery (exogenous).235 These
early or delayed infections are developed during the initial 3 to
24 months after implantation and commonly require a high
concentration of antibiotic in the following week after surgery.
Thus, the use of elution profiles in the form of high dosage
peaks during the first days, which rapidly decay in the coming
week but with maintained antibiotic levels still present a
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month later has been encouraged.227,235 The current approach
may be effective in the treatment of early infections, although
the reduction in antibiotic load poses a problem for late stage
infections occurring more than 24 months after implantation,
where the reduction in antibiotic load may stimulate AMR.
Statistics have shown that the likelihood of suffering a late
stage infection after arthroplasty can be similar to early and
delayed infections (30, 29 and 41%, respectively),236,237
suggesting that current elution profiles should be modified.
To promote a higher release in the late stages after implan-
tation, several novel antimicrobial delivery approaches are
under development (Fig. 5).
One such localised delivery approach is to anchor a desired
antibiotic to the implanted device surface in a single
(Fig. 5a)238 or multi-layered fashion (Fig. 5b).239 Other systems
have focused on direct modification of implant surfaces and
geometries to tailor antibiotic delivery, such as varying
channel placement (Fig. 5c).240 Nevertheless, modification of
implants may be difficult depending on the selected manufac-
turing and antimicrobial technologies, therefore the addition
of carriers acting as antibiotic delivery systems is becoming of
special interest to the field. These materials can be mixed into
cement formulations and prepared with minimal changes to
the current methodology, resulting in a myriad of possible
configurations. Some technologies rely on the attachment of
antibiotic molecules to particles in the nano to micro scale
(Fig. 5d and e).241,243 In contrast to simple attachment, anti-
biotic encapsulation is an alternative approach (Fig. 5f), pro-
viding a more controlled form of elution and protection
during curing in the form of metallic nanoparticles,235 lipo-
somes242 or as a multilayer assembly for bone cement.244,245
Nevertheless, most of these approaches have been shown to
have detrimental effects on the final product, with reduced
mechanical properties or limited initial elution. This effect,
and the poor understanding of the elution requirements
needed to prevent AMR, indicate that there is a critical need to
research antibiotic delivery systems and further our under-
standing of their influence on resistance development.231,235
Although the use of PMMA bone cements is highly wide-
spread, reports have shown a significant persistence of infec-
tion associated with residual particles.246,247 Cement and
implant debris can result in local inflammatory activity,
leading to chronic complications and aseptic loosening.225
These potential negative outcomes and other disadvantages of
PMMA bone cements, namely their lack of bioactivity or osseo-
conductivity, heat generation during curing, expansion due to
Fig. 5 Examples of alternative delivery systems currently explored in the literature with examples for (a) implant antibiotic attachment as a mono-
layer,238 (b) multilayer,239 (c) direct implant modification,240 (d) particle tethering,241 antibiotic incorporation to (e) nanoparticles235 or (f ) lipo-
somes.242 Adapted from the source material.
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water absorption and the potential allergic reaction to
monomer remnants, has pushed forward the development of
different formulations. One of the second-generation bioma-
terials employed in regenerative medicine is calcium and
hydroxyapatite bone cement. These materials share a large
similarity with natural bone where calcium and phosphate
ions result in the promotion of osteoconduction and osteogen-
esis with antibiotic loading becoming an interesting research
niche.248,249 Similarly, zinc polycarboxylate and glass polyalk-
enoate formulations have enhanced biological properties com-
pared to common PMMA cements, making these materials
especially popular in the dental field.250 Besides antibiotic
loading (i.e. fusidic acid) it must be said that other anti-
microbial agents are regularly used as antibacterial additives
(i.e. Chlorhexidine diacetate or Benzalkonium chloride).251
The interest in developing antibiotic loaded cements to
provide a sustained therapy and controlled dosage may result
in a lower risk of infection, nonetheless, with AMR on the rise
there is also a critical need to develop and implement novel
antimicrobial substances. The natural antimicrobial activity of
some metallic ions against bacteria252–254 has encouraged
their use in medical devices, however, their potential toxic
effects has restricted use with only a few candidates being
granted governmental approval following successful market-
ing. One such element is silver for which the number of anti-
microbial based products has elevated from 200 to nearly 1400
over the last decade.255 Examples include touch surfaces (“Safe
Touch”, Dorset), hand sanitizers (Evolut Silver), textiles (Silver
Plus®), dressings (Mepilex® Ag) and implant coatings
(Agluna®), yet silver loaded cements are still not commercially
accessible. Although the available literature presents research
on cements loaded with different Ag donors, the detrimental
effect that some silver salts have on the curing process of
PMMA bone cement has moved the field onto a preferential
use of silver nanoparticles (AgNPs).256–259 This form of silver
presents a high surface area to volume ratio, conferring desir-
able chemical and physical properties to enhance anti-
microbial efficacy.260 Specifically, AgNPs loaded PMMA bone
cement tested in vitro reveal a broad antimicrobial spectrum
against both Gram positive and Gram negative species, never-
theless of special interest is the high effectivity against anti-
biotic resistance strains showcased by Bistolfi et al.227 These
promising results alongside the recent publishing of a clinical
trial suggesting the safety of AgNPs loaded cements in vivo,261
solidify the rationale behind the use of this heavy metal to
tackle AMR. That said, there is a limited understanding on the
antimicrobial efficacy of silver particle loaded cements in vivo
with only one animal model published to date.262 In this
report, Moojen et al. carried out the analysis of AgNPs loaded
cements in a rabbit infection model with no significant
reduction of S. aureus colony forming units between loaded
and plain cements after 14 days. Interestingly, available
literature263–265 points to silver nanoparticles as an effective
antimicrobial in vitro, indicating a disconnection between lab-
oratory and animal methods. This detachment between in vitro
and in vivo models in antimicrobial testing is not an isolated
occurrence. Cytotoxicity and other cell work testing methods
broadly used in the field have been shown to have a poor corre-
lation with animal models.266
Alongside silver, other metals and non-organic species are
being studied for their future application in antimicrobial loaded
cements. Copper, gold, magnesium, zinc and their oxides have
been successfully mixed with bone cements to confer anti-
microbial properties, while graphene, paraben, quaternary amine
monomers or chitosan are some of the more common non-
metallic antimicrobial additives.227,267 Nevertheless, the clinical
relevance of these technologies is diminished by the limited bio-
logical assessment available in vitro, with little immune response,
hemocompatibility or genotoxicity studies available in most
manuscripts. Thus, there is a need to develop more fundamental
work on promising antimicrobial agents while revisiting old and
over simplistic in vitro testing methods for the development,
screening and implementation of new therapies.
The oversimplification of physiologically relevant processes
is not only constrained to cell culture. To test the antibacterial
effectiveness of antimicrobial materials it is common to
employ a single pathogenic bacterial species generally found
in clinical settings for the intended application of the bioma-
terial. Nevertheless, utilising single-species planktonic cultures
for in vitro modelling does not compare to clinical reality. An
extreme case is the oral microbiome where over 700 species
have been identified in the human oral cavity, suggesting that
single bacterium are not representative of the complex and
mutable in vivo environment.268 Therefore, evaluating anti-
microbial approaches to material design requires models of
physiologically relevant environments that are likely to incor-
porate bacteria as a biofilm (possibly multispecies), a relevant
implant material, and flow conditions.269 Several studies have
incorporated these elements successfully to evaluate clinical
implant materials such as titanium and zirconium, however
they have not been frequently utilized in the development of
antimicrobial biomaterials.269–271 Incorporating multiple disci-
plines, including biology, engineering, and mathematics is
likely to become decisive to furthering the field due to the
multifaceted nature of co-culture systems.272
As the regulatory pipeline becomes more time and cost con-
suming, it is important to develop a strong case to ensure
present and future stakeholder participation. Silver is an
attractive antimicrobial thanks to its status as an approved bio-
material, thus, it is possible to ease some of the requirements
using predicate devices. Innovation and state of the art
research should be a must to tackle AMR, nonetheless, the end
purpose of novel technologies should be commercialization.
Consequently, it is necessary to adapt the biomaterial commu-
nity methodology to encompass the regulatory process and its
application since the initial steps of promising technologies.
Future recommendations
At the start of the present manuscript, the complexity, risks
and costs of developing and bringing to market a novel health-
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care product were indicated. Over the following sections,
different strategies to tackle AMR were emphasized and,
through the use of two case studies, limitations on current bio-
materials approaches were highlighted. As most global
changes involving regulatory pathways can only receive a
limited push forward from the biomaterials field, our role
should be in the innovation and translation of new techno-
logies. Thus, the principal aim of the following section is to
clarify these limitations, identify clear areas of interest and put
forward recommendations where biomaterial science may
improve our response to AMR (Fig. 6).
From the available literature it is becoming increasingly
evident that promising materials tested in vitro may correlate
poorly with in vivo analysis, leading to failures in clinical
testing.266 Ethical and effectiveness concerns coupled with the
extensive fiscal and time expenditures needed for animal
testing has caused a decrease of such practices. Thus, special
focus on in vitro testing as a screening method to assess and
predict the host response to a biomaterial is being made.266
Despite this, as the number of novel healthcare technologies
discovered over the decades has quickened, development of
in vitro tests to ascertain their safety and effectiveness has
stagnated.273–275 Susceptibility tests are of great relevance to
analyse the interaction of antimicrobial agents and different
microorganisms with numerous standards available depend-
ing on the base material and its application. Albeit method-
ologies differ, they commonly involve the contact or submer-
sion of the desired material with a controlled bacterial density
or plated culture for a specific time, followed by recovery and
quantification or measurement of lack of growth on a plate.276
Comparison between controls and the antimicrobial agent
tested will make it possible to ascertain if a material is inert,
bacteriostatic or antimicrobial, helping to screen potential
novel materials to tackle AMR. These tests are relatively simple
with ordinary laboratory set ups required and timescales of
days or weeks.276,277 Similarly to antimicrobial analysis,
physicochemical tests rarely study biomaterials in a physiologi-
cal relevant state. Few manuscripts ensure that samples are
preconditioned with complex macromolecules or understand
the ability of the added functionality to last in the long term,
limiting the extrapolation of the obtained results to in vivo
models. Nonetheless, the attractiveness driven by their simpli-
city and recognized status as standards in the field has led to a
prevalence of such techniques without realising their potential
downsides.
The composition of growth media is another factor that is
rarely accounted for during testing and only changed depend-
ing on standards recommendations and the bacterial species
used.277 However, elements present such as nutrients or salts
to prevent osmotic shock can react with the desired molecule
and cation to bias the obtained results (i.e. copper and chlor-
ine).118 Similarly, timescales may be a misrepresentation of
the reality. Touch surfaces are quickly becoming of interest to
tackle HAI for which direct contact and recovery tests, such as
JIS Z2801:2010 are the norm.55 These typically require the
recovery of a deposited inoculum after 24 h of contact,
however studies have shown that most surface to hand or
hand to hand contact takes place in a few hours,55 demonstrat-
ing that long periods of time do not represent the reality of the
intended material and application. Besides media and time-
scales, the recovery and quantification of survival bacterial
populations may be another source of bias. This is commonly
done either by spectroscopy (i.e. optical density) or by detach-
ment of the bacterial biomass and plating, nevertheless, the
former does not discriminate between live and dead microor-
ganisms, while the latter requires complete recovery of bac-
terial species, which may be a challenge for porous or adhesive
materials.55 Consequently, the biomaterials community
should push forward the rework of such methods and encou-
rage the broad use of more novel techniques for antimicrobial
growth and AMR evaluation as suggested by Khan et al.278 and
Belkum et al.279
Fig. 6 Diagram showcasing critical areas for the biomaterials community to tackle AMR.
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Currently the biomedical field typically conducts testing
on bacterial and mammalian cells separately, which disre-
gards the complex interactions between cell types and
infected devices. Similarly, human bacteria flora is multi-
faceted, with numerous species interacting and exchanging
genetic information. Despite this, it is common to test for
single bacterium, disregarding most Horizontal Gene
Transfers (HGT) between bacterial species, commonplace for
the exchange of resistance genes.12,13 Thus, there is an over-
simplification of infection analysis in vitro in both bacterial
and mammalian cell culture analysis.280 The prime example
of such a scenario is the immune system, where white blood
cells have been demonstrated to play a fundamental role in
bone regeneration and infection control.281,282 Nonetheless,
it is common to simply conduct separate analysis for inflam-
mation, mineralization and antibacterial effectiveness of anti-
microbial agents with different single cell types disregarding
interactions. The selection of mammalian cells for each of
these tests is also a notable point. Cytotoxicity analysis
in vitro commonly entails the use of cells derived from
tumours, more resilient and less expensive than more rele-
vant cell lines, however, these do not necessary pose an accu-
rate model of the real human tissue and biomaterial
interaction.273,280 Similarly, most antimicrobial tests done
in vitro to test the antibacterial efficacy of novel biomaterials
involve laboratory strains, which may not be a real representa-
tion of the main clinical pathogens involved in infections.283
Consequently, as antimicrobial strategies continue to evolve
so must our pre-clinical testing regimes, being the creation of
a multicellular infection test, proper selection of bacteria and
cell lines, and improved correlation between in vivo and
in vitro models essential to progressing novel AMR prevention
strategies.
Analysis of natural resistance acquisition is another
aspect where the biomaterials community can help to chal-
lenge AMR. In drug development, it is usual to evaluate the
possibility of microorganisms gaining resistance to novel
and reworked molecules.20 Nevertheless, this trend is rarely
followed during the development of biomaterials techno-
logies where a focus on the initial efficacy of the system over-
rides long-term analyses. Such is the case for implantable
devices functionalised with antimicrobial agents, however,
these devices will need to halt infection for extended periods
of time. Taking into account the adaptability and flexibility
of bacteria, a lack of knowledge in the long-term effect of
novel technologies poses a threat to treatment strategies
focused on tackling AMR. This absence of long-lasting
efficacy is especially critical for the implementation of novel
molecules or antimicrobial metals, for which our under-
standing of the mechanisms driving AMR are still lacking.
An example would be silver, microbiologist are aware of Ag
resistant species and over the last decade genomic analysis
of such bacteria has led to the discovery of the gene thought
to encode silver resistance, the sil operon.284–286
Nevertheless, the natural acquisition of silver resistance is
rarely studied with limited papers available dealing with
long-term passages of controlled silver dosages to force
resistance.285–287 The overuse of silver and the possibility of
bacterial strains resistant to both antibiotics and heavy
metals has awoken an interest in natural resistance
development,288–291 exemplifying the importance of long-
term analysis of antimicrobials. As a consequence, it is
necessary to undertake such studies for novel biomaterials
in vitro and perform a more complete analysis of resistance
acquisition as suggested by Martínez et al.274
Moving forward, it is important that the way microorgan-
isms develop resistance is understood so that appropriate
treatments may be identified. It is well documented that
microorganisms have what is known as intrinsic resistance,
or the natural ability to resist an antimicrobials mechanism
of action, which can occur at two stages: planktonic and com-
munity level.292 Resistance within an organism can occur due
to gene mutation or by HGT293 when DNA is acquired from
another resistant organism.294 This process can arise from
the up-take of free DNA (transformation), plasma-mediated
transfer (conjugation) or phage-mediated transfer (transduc-
tion).295 Community level organisms can develop further re-
sistance and tolerate far greater stress than individual cells.
This is demonstrated by the formation of biofilms that may
increase antibiotic resistance up to 1000-fold.296 Due to the
significant implication that the formation of a biofilm has on
the ability of an organism to resist treatment, future develop-
ments may aim to provide approaches that disrupt or negate
this effect.
Alongside this necessity to better understand resistance
development, it is required to understand the limitations of
current dosage analysis in resistance analysis and its preven-
tion. The use of MIC to describe and classify an anti-
microbial is a helpful tool for microbiologist and biomater-
ial scientist who are tackling AMR297–299 and is commonly
analysed by subjecting controlled concentrations of the
desired material to a specific density of a bacterial species
either in liquid media or agar plated. After incubation, cul-
tures are inspected visually or through spectroscopy to deter-
mine bacterial growth in the liquid media or to assess the
size of the inhibition zone created in agar plates.297,299 For
common drugs, standards are available with MIC break-
points to determine if a specific bacteria species is suscep-
tible, intermediate or resistant to the selected antibiotic
which facilitates the following treatment.300 Thus, MIC has
become one of the main tools available to select dosage in
the biomaterials community. Nevertheless, by definition the
MIC only inhibits the growth of bacteria, with cells still able
to survive, but not proliferate, possibly still present in the
culture. In contrast, plating of liquid cultures after antibiotic
treatment and incubation provide the minimum bactericidal
concentration (MBC), revealing the real amount of anti-
microbial needed to kill the desired bacterial species.301 The
range of antibiotic concentrations between MIC and MBC
can led to a lower dosage being decided where resistant bac-
terial cells can be selected, enhancing AMR acquisition. This
has been recognised in the mutant selection hypothesis
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where drug-resistant subpopulations present before treat-
ment are enriched and amplified if the antimicrobial con-
centrations fall within a specific range.124 To prevent such a
scenario, authors have shown that dosage selection should
be complemented with parameters accounting for the
mutant selection window, proposing the MPC
(Fig. 4a).129,302 Selection of antimicrobial dosages taking the
MPC into account will mean mutants fail to amplify124 and
will provide a more robust dosage tool.
Further to the antimicrobial dosage being above the MPC,
delivery systems should be fine-tuned in order to produce a
pharmacokinetic release profile that enables this concen-
tration to be maintained over the treatment period. This can
be achieved by developing release kinetics that allow for the
MPC to be exceeded shortly after the target site is reached.125
If the antimicrobial concentration is likely to fall below MPC
values during treatment combination therapies or novel
dosing profiles (Fig. 4b) should be exploited. In addition to the
systemic administration of antimicrobials, localised delivery is
highlighted as being preferential in order to prevent AMR.
This is because it enables a more targeted approach that does
not expose the rest of the body to systemic effects, including
that of engaging with other microorganisms.303
As the crucial step to bring a novel technology to the
market, regulatory approval should be considered as part of
the initial steps of novel device research. The nature of
contact between device and body, length of contact time and
other parameters will decide the regulatory pathway, which
will ultimately determine the economic and time investment
required.22 As the main link between technical specifica-
tions and regulators, biomaterial researchers should be
aware of the implications that the developed technology has
in the future regulatory process and ensure that all pre-
clinical data meets governmental requirements. This will
require knowledge of the healthcare pipelines,304,305
however, the complexity of these processes makes it difficult
to encompass all possible facets.22,275 Thus, it is necessary
to focus on the two main aspects where one may have the
highest impact in a multidisciplinary group: device categor-
ization and preclinical testing. The first hurdle to be tackled
consists in properly defining the technology and its
intended purpose. If the novel technology intends to act as
an implantable with added functionality, such as an anti-
microbial coated implant, it will be recognised as a medical
device which will follow the European Union Medical Device
Regulations (MDR) 2017/745 and 2017/746. These divide
medical devices into four categories (Class I, IIa, IIb and III)
with increasingly difficult regulatory processes to be met. In
contrast, if the developed material is mainly intended to
correct or modify a physiological function by exerting a
pharmacological, immunological or metabolic action, such
as a novel molecule, this will mark the product as a medic-
inal agent, following Regulation (EC) No 726/2004 and
Directive 2001/83/EC with extensive clinical trials
required.306,307 During the inception of the novel biomater-
ials technology, proper knowledge of these classifications,
requirements and similar marketed products alongside fun-
damental expertise can make it possible to modify the novel
product and test it before further steps are taken. This fine-
tuning prior to regulatory processes begin would ensure that
costly reworks are prevented.308
The amount of preclinical data to demonstrate the effec-
tiveness and safety of medical devices is dependent on the
technology. In Europe, ISO 10993 2018 provides insight into
the assays, data and quality control necessary for the in vitro
testing of these devices (Fig. 7). Once the end category of the
device is known, in vitro tests can be arranged following ISO
10993 recommendations. This will be done first through any
“in house” capabilities available, limiting failures of future
independent tests and early cheaper rework if necessary. It
must be pointed out that there may be an apparent contradic-
tion with the previous recommendation to develop and apply
novel analytical methods. Nevertheless, tests mentioned and
referenced in ISO 10993 are standardized methodologies,
which in some cases have been shown to be outdated or
poorly correlated with clinical outcomes.266,309–311 ISO 10993
takes into account the novelty of the field and the idiosyncra-
sies inherent to novel devices up to some extent, “It is not
intended that ISO 10993 provide a rigid set of test methods,
including pass/fail criteria, as this might result in either an
unnecessary constraint on the development and use of novel
medical devices, or a false sense of security in the general use
of medical devices. Where a particular application warrants
it, experts in the product or in the area of application con-
cerned can choose to establish specific tests and criteria,
described in a product-specific vertical standard.” However,
technology progression still requires an approved method-
ology, limiting the current tests available to undertake.
Consequently, it is still possible to encourage the use of
better predictive analysis for future development of better
standards.
Scientific work has become a competitive field since the
early 2000s where a novel philosophy of “publish or perish”
has taken hold.312 This change in mentality and all previously
commented barriers to medical device approval and marketing
led to a preference of publications over patents and, although
this trend is changing, article writing is still the preferred
outcome.313 Publishing instead of filing a patent ensures that
the novel technology is broadly open to the public, which
diminishes the prospects of future commercialization. Thus, it
is necessary to continue exploring novel approaches to tackle
AMR while ensuring that promising technologies are not lost.
To achieve such an objective, greater involvement between aca-
demia and industry is needed. Finally, it has been shown that
part of AMR emergence has been caused by poor use of anti-
biotics and lack of understanding of antibiotic resistance by
the public.16 Academics have a privileged position from which
to help by educating in the danger posed by bacterial resis-
tance and the role of the public in tackling AMR.
Consequently, enhancing public engagement, including AMR
awareness courses would result in higher penetration of
current policies.37
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Conclusions
Antibiotic resistance in pathogenic bacteria is driving modern
medicine to a bleak future where effective therapies against
infection may become scarce. With prospects of a post-anti-
biotic era on the horizon, numerous organizations have
focused their efforts on unearthing the causes behind such
phenomena, with both bacterial and human causes identified.
Over billions of years, bacterial cells have developed numerous
mechanisms to survive and adapt to toxic substances, which
coupled with their genomic plasticity, rapid life cycles and
large populations, promotes development of antibiotic resis-
tance. Nevertheless, human mismanagement of antibiotics
has selected for high prevalence of resistant organisms, exacer-
bating AMR emergence. This coupled with the complexity
inherent in their development and the high risk and low
revenue associated with these substances has resulted in a
paradox where novel antimicrobials are critically required,
however, few products are currently in the development pipe-
line. This has led to action plans being developed and
Fig. 7 Considerations for biological assessment from ISO 10993-1:2018 where “X” means prerequisite information needed for a risk assessment; “E”
means endpoints to be evaluated on the risk assessment (either through the use of existing data, additional endpoint-specific testing, or a rationale
for why assessment of the endpoint does not require an additional data set assessment).
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implemented by governmental bodies since the early 2000s.
However, the complexity of AMR and the intricacy of moving
large relevant associations forward calls for action at all levels.
The biomaterials community, as one of the main innovation
sources, has responded to the threat posed by AMR with
increasing development of materials, substances and delivery
systems conceived to halt the prospects of a post-antibiotic
era. In this paper, we have conducted a review of available lit-
erature to showcase promising technologies under develop-
ment and, through two case studies, pinpointed the following
areas where special focus should be given to push forward a
focused front against AMR:
• Continue the current development of novel antimicro-
bials and delivery systems.
• Develop our understanding of the long-term influence
of novel substances and delivery systems on AMR to comp-
lement current short-term analysis.
• Rework simplistic in vitro analysis broadly used for rele-
vant correlation with in vivo analysis.
• Enhance the understanding of requirements and pro-
cesses behind commercialization of these products to guide
the initial research stages.
• Enhance AMR awareness at all levels.
Moving forward, a focus on these areas will make it possible
to reduce prospects of bacteria gaining novel resistances,
ensure that promising technologies in vitro will maintain their
effectiveness in vivo, reduce costly reworks and failures during
regulatory approval and increase the overall response to AMR.
Consequently, novel therapies will retain their effectiveness
with a smoother transition between laboratory and market,
enhancing the critical role of the biomaterial community in
confronting AMR.
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